TW266160B - - Google Patents

Info

Publication number
TW266160B
TW266160B TW082102157A TW82102157A TW266160B TW 266160 B TW266160 B TW 266160B TW 082102157 A TW082102157 A TW 082102157A TW 82102157 A TW82102157 A TW 82102157A TW 266160 B TW266160 B TW 266160B
Authority
TW
Taiwan
Application number
TW082102157A
Original Assignee
Nippon Chemicals Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemicals Pharmaceutical Co Ltd filed Critical Nippon Chemicals Pharmaceutical Co Ltd
Application granted granted Critical
Publication of TW266160B publication Critical patent/TW266160B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW082102157A 1992-04-03 1993-03-23 TW266160B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10905392 1992-04-03

Publications (1)

Publication Number Publication Date
TW266160B true TW266160B (zh) 1995-12-21

Family

ID=14500416

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082102157A TW266160B (zh) 1992-04-03 1993-03-23

Country Status (14)

Country Link
US (1) US5512298A (zh)
EP (1) EP0563697B1 (zh)
KR (1) KR100267525B1 (zh)
CN (1) CN1039673C (zh)
AU (1) AU657044B2 (zh)
BR (1) BR9301373A (zh)
CA (1) CA2093258C (zh)
CZ (1) CZ282844B6 (zh)
DE (1) DE69330392T2 (zh)
ES (1) ES2160582T3 (zh)
HU (1) HU217810B (zh)
PL (1) PL171011B1 (zh)
RU (1) RU2116069C1 (zh)
TW (1) TW266160B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074991A1 (ja) * 2004-02-09 2005-08-18 Kabushiki Kaisha Sangi 抗腫瘍剤
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
JP5097540B2 (ja) * 2005-04-06 2012-12-12 株式会社サンギ 腸管吸収用抗腫瘍剤
EP2286800A1 (en) * 2005-04-11 2011-02-23 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
RU2657833C2 (ru) * 2015-12-01 2018-06-15 Общество С Ограниченной Ответственностью "Остерос Биомедика" Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение
EA030671B1 (ru) 2016-07-20 2018-09-28 Общество С Ограниченной Ответственностью "Остерос Биомедика" Препарат для лечения костных поражений, вызванных злокачественными новообразованиями

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859431A (en) * 1973-01-04 1975-01-07 Lilly Industries Ltd Drug formulations
JPS552601A (en) * 1978-06-20 1980-01-10 Yamasa Shoyu Co Ltd Anti-tumor agent for non-injection use
US4681765A (en) * 1984-09-13 1987-07-21 American Home Products Corporation Rapid releasing triamterene containing gelatin capsule dosage forms for once daily antihypertensive use
EP0239015B1 (en) * 1986-03-24 1991-10-16 Nippon Kayaku Kabushiki Kaisha Process for producing 1-beta-d-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof, and pharmaceutical composition containing the latter
KR880701098A (ko) * 1986-04-01 1988-07-25 로버어트 에이 아미테이지 메틸프레드니솔론/소디움 카르복시메틸 전분 정제 조성물
US5223503A (en) * 1991-04-29 1993-06-29 Eli Lilly And Company 6-substituted pyrido[2,3-d]pyrimidines as antineoplastic agents

Also Published As

Publication number Publication date
KR930021206A (ko) 1993-11-22
KR100267525B1 (ko) 2000-12-01
CA2093258A1 (en) 1993-10-04
PL298338A1 (en) 1993-12-13
DE69330392T2 (de) 2001-11-08
HU9300974D0 (en) 1993-06-28
HUT65314A (en) 1994-05-02
CA2093258C (en) 2003-01-14
CZ57793A3 (en) 1994-02-16
EP0563697B1 (en) 2001-07-04
CN1077888A (zh) 1993-11-03
HU217810B (hu) 2000-04-28
CZ282844B6 (cs) 1997-10-15
EP0563697A2 (en) 1993-10-06
BR9301373A (pt) 1993-10-13
EP0563697A3 (en) 1994-06-01
PL171011B1 (pl) 1997-02-28
AU657044B2 (en) 1995-02-23
DE69330392D1 (de) 2001-08-09
ES2160582T3 (es) 2001-11-16
AU3555893A (en) 1993-10-07
CN1039673C (zh) 1998-09-09
US5512298A (en) 1996-04-30
RU2116069C1 (ru) 1998-07-27

Similar Documents

Publication Publication Date Title
TW234129B (zh)
BR9304651A (zh)
DK0554977T3 (zh)
DK0588007T3 (zh)
TW221369B (zh)
DK0581129T3 (zh)
FR2686828B1 (zh)
DK0574276T3 (zh)
DK0596569T3 (zh)
DK0581726T3 (zh)
DK0571172T3 (zh)
BR9202713C1 (zh)
TW236717B (zh)
DE9209779U1 (zh)
TW247271B (zh)
AU632452B2 (zh)
IN185593B (zh)
IN185919B (zh)
AU1109992A (zh)
CN3013212S (zh)
AU1708392A (zh)
AU1707592A (zh)
AU1610792A (zh)
AU1136092A (zh)
AU1844392A (zh)